I-NEW YORK – I-Immunocore ithe ngoMsombuluko izothengisa amasheya angu-3,733,333 esivumelwaneni sokuxhasa ngezimali i-private equity investment (PIPE) okulindeleke ukuthi siqoqe amaRandi ayizigidi ezingu-140.
Ngaphansi kwesivumelwano, i-Immunocore izothengisa isitoko sayo esivamile kanye nesitoko esivamile esingavotelwa ngo-$37.50 ngesabelo ngasinye. Abatshalizimali benkampani abakhona ababambe iqhaza kulolu xhaso lwezimali bahlanganisa i-RTW Investments, iRock Springs Capital kanye neGeneral Atlantic. Isivumelwano se-PIPE kulindeleke ukuthi siphele ngoJulayi 20.
Le nkampani izosebenzisa imali engenayo ukuxhasa abantu abazongenela ukhetho lomdlavuza kanye nezifo ezithathelwanayo, okuhlanganisa nokuthuthukiswa komuntu ozobe ehola ukhetho lomdlavuza, iKimmtrak (tebentafusp-tebn), ukwelapha isikhumba esihle se-HLA-A*02:01 kanye ne-melanoma ene-uveal. Uxhaso, kanye nemali engenayo evela kuKimmtrak, kulindeleke ukuthi luxhase imisebenzi ye-Immunocore kuze kube ngu-2025.
Kulo nyaka, iKimmtrak ivunyelwe ukusetshenziswa ezigulini ezine-HLA-A*02:01 positive engasuswa noma i-metastatic uveal melanoma e-US, eYurophu nase-UK, phakathi kwamanye amazwe. I-Immunocore iyaqhubeka nokufunda lo muthi ocwaningweni lweSigaba I/II ku-HLA-A*02:01-positive cutaneous melanoma.
I-Immunocore iphinde ithuthukise ezinye izinhlobo ezine ze-oncology, okuhlanganisa nemithi emibili eyengeziwe ye-T-cell receptor ezivivinyweni zeSigaba I/II ezinhlamvini eziqinile ezithuthukisiwe. Omunye wemithi wenzelwe iziguli ezine-HLA-A*02:01-positive kanye ne-MAGE-A4-positive, kanti omunye uhlose i-HLA-A*02:01 kanye ne-PRAME-positive. Le nkampani futhi inazo izinhlobo ezimbili ze-oncology ezingadalulwanga ekuthuthukisweni kwangaphambi kokwelashwa.
Inqubomgomo Yobumfihlo.imigomo Nemibandela.Ilungelo Lokushicilela © 2022 GenomeWeb, iyunithi yebhizinisi leCrain Communications.wonke amalungelo agodliwe.